A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of XXXX in mild to moderate hypertensive patients.

Summary: The treatment period is of 12 months (dosing interval Q6M) and is composed

of 2 parts: Part 1: 6 month treatment period comprising 4 active arms at different

doses (75, 150, 300 and 600 mg) and one placebo. Part 2: 6 month treatment period in which all patients on placebo and 75 mg dose will be re-randomized to one of the 3 active arms (150, 300

and 600 mg) and those patients already receiving active treatment will continue to do so.

Type of study (PIC, Recruiting):  Recruiting

Commercial Study - Site Identification form required to be completed, please find Site ID form uploaded to study documents link below. 

Practice Activity: See part B and Schedule of Events

Practice Eligibility Criteria: GP practices within East Midlands

Practice Target: 3 per site

Is this Study Applicable for RSI Scheme?  

Yes, applicable for RSI scheme 

Research Costs: 

Commercial research studies follow a national tariff guideline. Click here for more information on the tariff or download the tariff by clicking here